Thrombin inhibition by novel benzamidine derivatives: A free-energy perturbation study

Journal of Medicinal Chemistry

Volumn 45, Issue 23, 2002, Pages 4995-5004

  Guimarães, Cristiano Ruch Werneck ^a,b   De Alencastro, Ricardo Bicca ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b YALE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZAMIDINE DERIVATIVE; THROMBIN INHIBITOR;

ANALYTIC METHOD; ARTICLE; BLOOD CLOTTING; CATALYSIS; COMPLEX FORMATION; ENZYME ACTIVE SITE; HYDRATION; HYDROPHOBICITY; MOLECULAR INTERACTION; THERMODYNAMICS; THROMBOCYTE AGGREGATION;

EID: 0037038313     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm020123p     Document Type: Article

References (45)

1. Coburn, C. A.; Rush, D. M.; Williams, P. D.; Homnick, C.; Lyle, E. A.; Lewis, S. D.; Lucas, B. J., Jr.; Di Muzio-Mower, J. M.; Juliano, M.; Krueger, J. A.; Vastag, K.; Chen, I.-W.; Vacca, J. P. Bicyclic pyridones as potent, efficacious and orally bioavailable thrombin inhibitors. Bioorg. Med. Chem. Lett. 2000,10, 1069- 1072.
2. Pavone, V.; De Simone, G.; Nastri, F.; Galdiero, S.; Staiano, N.; Lombardi, A.; Pedone, C. Multiple binding mode of reversible synthetic thrombin inhibitors. A comparative structural analysis. J. Biol. Chem. 1998, 379, 987-1006.
3. Lee, K. Recent progress in small molecule thrombin inhibitors. Korean J. Med. Chem. 1997, 7 (2), 127-144.
4. Kimbal, S. D. Thrombin active site inhibitors. Curr. Pharm. Des. 1995, 1, 441-468.
5. Ripka, W. C. New Thrombin inhibitors in cardiovascular disease. Curr. Opin. Chem. Biol. 1997, 1, 242-253.
6. Wienand, A.; Ehrhardt, C.; Metternich, R.; Tapparelli, C. Design, synthesis and biological evaluation of selective boron-containing thrombin inhibitors. Bioorg. Med. Chem. Lett. 1999, 7, 11295-1307.
7. Lu, T.; Soll, R. M.; Illig, C. R.; Bone, R.; Murphy, L.; Spurlino, J.; Salemme, F. R.; Tomczuk, B. E. Structure-Activity and crystallographic analysis of a new class of non-amide-based thrombin inhibitor. Bioorg. Med. Chem. Lett. 2000, 10, 79-82.
8. Lu, T.; Tomczuk, B.; Bone, R.; Murphy, L.; Salemme, F. R.; Soil, R. M. Non-Peptidic phenyl-based thrombin inhibitors: Exploring structural requirements of the s1 specificity pocket with amidines. Bioog. Med. Chem. Lett. 2000, 10, 83-85.
9. Lee, K.; Jung, W.-H.; Kang, M.; Lee, S.-H. Noncovalent thrombin inhibitors incorporating an imidazolylethynyl p1. Bioorg. Med. Chem. Lett. 2000, 10, 2775-2778.
10. Lumma, W. C., Jr.; Witherup, K. M.; Tucker, T. J.; Brady, S. F.; Sisko, J. T.; Naylor-Olsen, A. M.; Lewis, S. D.; Lucas, B. J.; Vacca, J. P. Design of novel, potent, noncovalent inhibitors of thrombin with nonbasic p-1 substructures: Rapid structure-activity studies by solid-phase synthesis. J. Med. Chem. 1998, 41, 1011-1013.
11. Babine, R. E.; Bender, S. L. Molecular recognition of protein-ligand complexes: Applications to drug design. Chem. Rev. 1997, 97 (5), 1359-1472.
12. Jones-Hertzog, D. K.; Jorgensen, W. L. Binding affinities for sulfonamide inhibitors with human thrombin using Monte Carlo simulations with a linear response methodology. J. Med. Chem. 1997, 40, 1539-1549.
13. Chen, Z.; Li, Y.; Mulichak, A. M.; Lewis, S. D.; Shafer, J. A. Crystal structure of human α-thrombin complexed with hirugen and p-amidinophenylpyruvate at 1.6 å resolution. Arch. Biochem. Biophys. 1995, 322 (1), 198-203.
14. Banner, D.; Hadváry, P. Crystallographic analysis at 3.0-Å resolution of the binding to human thrombin of four active site-directed inhibitors. J. Biol. Chem. 1991, 266 (30), 20085-20093.
15. Scozzafava, A.; Briganti, F.; Supuran, C. T. Protease inhibitors - Part 3. Synthesis of non-basic thrombin inhibitors incorporating pyridinium-sulfanilylguanidine moieties at the p1 site. Eur. J. Med. Chem. 1999, 34, 939-952.
16. Tucker, T. J.; Brady, S. F.; Lumma, W. C.; Lewis, S. D.; Gardell, S. J.; Naylor-Olsen, A. M.; Yan, Y.; Sisko, J. T.; Stauffer, K. J.; Lucas, B. J.; Lynch, J. J.; Cook, J. J.; Stranieri, M. T.; Holahan, M. A.; Lyle, E. A.; Baskin, E. P.; Chen, I.-W.; Dancheck, K. B.; Krueger, J. A.; Cooper, C. M.; Vacca, J. P. Desing and synthesis of a series of potent and orally bioavailable noncovalent inhibitors that utilize nonbasic groups in the p1 position. J. Med. Chem. 1998, 41, 3210-3219.
17. Bone, R.; Lu, T.; Illig, C. R.; Soll, R. M.; Spurlino, J. C. Structural analysis of thrombin complexed with potent inhibitors incorporating a phenyl group as a peptide mimetic and aminopyridines as guanidine substitutes. J. Med. Chem. 1998, 41, 2068-2075.
18. Lumma, W. C., Jr.; Witherup, K. M.; Tucker, T. J.; Brady, S. F.; Sisko, J. T.; Naylor-Olsen, A. M.; Lewis, S. D.; Lucas, B. J.; Vacca, J. P. Design of novel, potent, noncovalent inhibitors of thrombin with nonbasic p-1 substructures: Rapid structure-activity studies by solid-phase synthesis. J. Med. Chem. 1998, 41, 1011-1013.
19. Isaacs, R. C. A.; Cutrona, K. J.; Newton, C. L.; Sanderson; P. E. J.; Solinsky, M. G.; Baskin, E. P.; Chen, I.-W.; Cooper, C. M.; Cook, J. J.; Gardell, S. J.; Lewis, S. D.; Lucas Jr., R. J.; Lyle, E. A.; Lynch, J. J., Jr.; Naylor-Olsen, A. M.; Stranieri, M. T.; Vastag, K.; Vacca, J. P. C6 modifications of the pyridone core of thrombin inhibitor l-374,087 as a means of enhancing its oral absorption. Bioorg. Med. Chem. Lett. 1998, 8, 1719-1724.
20. Sanderson, P. E. J.; Lyle, T. A.; Cutrona, K. J.; Dyer, D. L.; Dorsey, B. D.; McDonough, C. M.; Naylor-Olsen, A. M.; Chen, I.-W.; Chen, Z.; Cook, J. J.; Cooper, C. M., Gardell, S. J.; Hare, T. R.; Krueger, J. A.; Lewis, S. D.; Lin, J. H.; Lucas, B. J., Jr.; Lyle, E. A.; Lynch, J. J., Jr.; Stranieri, M. T.; Vastag, K.; Yan, Y.; Shafer, J. A.; Vacca, J. P. Efficacious, orally bioavailable thrombin inhibitors based on 3-aminopyridinone or 3-aminopyrazinone acetamide peptidomimetic templates. J. Med. Chem. 1998, 41, 4466-4474.
21. Tucker, T. J.; Lumma, W. C.; Lewis, S. D.; Gardell, S. J.; Lucas, B. J.; Baskin, E. P.; Woltmann, R.; Lynch, J. J.; Lyle, E. A.; Appleby, S. D.; Chen, J. W.; Dancheck, K. B., Vacca, potent noncovalent thrombin inhibitors that utilize the unique amino acid d-dicyclohexylalanine in the p3 position. Implications on oral bioavailability and antithrombotic efficacy. J. P. J. Med. Chem. 1997, 40, 1565-1569.
22. Lee, K.; Hwang, S. Y.; Park, C. W. Thrombin inhibitors based on a propargylglycine template. Bioorg. Med. Chem. Lett. 1999, 9, 1013-1018.
23. Bachand, B.; Tarazi, M.; St-Denis, Y.; Edmunds, J. J.; Winocour, P. D.; Leblond, L. Siddiqui, M. A. Potent and selective bicyclic lactam inhibitors of thrombin. Part 4: Transition state inhibitors. Bioorg. Med. Chem. Lett. 2001, 11, 287-290.
24. Zwanzig, R. High-Temperature equation of state by a perturbation method. I. Nonpolar gases. J. Chem. Phys. 1954, 22 (8), 1420-1426.
25. Beveridge, D. L.; DiCapua, F. M. Free energy via molecular simulations. Annu. Rev. Biophys. Biophys. Biochem. 1989, 18, 431-492.
26. Jorgensen, W. L. Free energy calculations: A breakthrough for modeling organic chemistry in solution. Acc. Chem. Res. 1989, 22, 184-189.
27. Kollman, P. A. Free energy calculations: Applications to chemical and biochemical phenomena. Chem. Rev. 1993, 93, 2395-2417.
28. Wong, C. F.; McCammon, A. Dynamics and design of enzymes and inhibitors. J. Am. Chem. Soc. 1986, 108 (13), 3830-3832.
29. Mezei, M. The finite difference thermodynamic integration, tested on calculating the hydration free energy difference between acetone and dimethylamine in water. J. Chem. Phys. 1987, 86 (12), 7084-7088.
30. Guimarães, C. R. W.; Bicca de Alencastro, R. Thermodynamic analysis of thrombin inhibition by benzamidine and p-methylbenzamidine via free-energy perturbations: Inspection of intraperturbed-group contributions using the finite difference thermodynamic integration (FDTI) algorithm. J. Phys. Chem. B 2002, 106 (2), 466-476.
31. Guimarães, C. R. W.; Bicca de Alencastro, R. Evaluating the relative free energy of hydration of new thrombin inhibitor candidates using the finite difference thermodynamic integration (FDTI) method. Int. J. Quantum Chem. 2001, 85, 713-726.
32. Dauber-Osguthorpe, P.; Roberts, V. A.; Osguthorpe, D. J.; Wolff, J.; Genest, M.; Hagler, A. T. Structure and energetics of ligand binding to proteins: E. coli dihydrofolate reductase-trimethroprim, a drug-receptor system. Proteins: Struct., Funct., Genet. 1988, 4, 31-47.
33. MacKerell, A. D.; Bashford, D.; Bellott, M.; Dunbrack, R. L.; Evanseck, J. D.; Field, M. J.; Fischer, S.; Gao, J.; Guo, H.; Ha, S.; Joseph-McCarthy, D.; Kuchnir, L.; Kuczera, K.; Lau, F. T. K.; Mattos, C.; Michnick, S.; Ngo, T.; Nguyen, D. T.; Prodhom, B.; Reiher, W. E.; Roux, B.; Schlenkrich, M.; Smith, J. C.; Stote, R.; Straub, J.; Watanabe, M.; Wiorkiewicz-Kuczera, J.; Yin, D.; Karplus, M. All-atom empirical potential for molecular modeling and dynamics studies of proteins. J. Phys. Chem. B 1998 102 (18), 3586-3616.
34. Hansson, T.; Åqvist, J. Estimation of binding free energies for hiv proteinase inhibitors by molecular dynamics simulations. Protein Eng. 1995, 8 (11), 1137-1144.
35. - from statistical perturbation theory. Chem. Phys. 1989, 129, 193-200.
36. Ågvist, J. Ion-Water Interaction potentials derived from free energy perturbation simulations. J. Phys. Chem. 1990, 94, 8021-8024.
37. Åqvist, J. Modelling of Ion-Ligand Interactions in Solutions and Biomolecules. J. Mol. Struct. (THEOCHEM) 1992, 256, 135-152.
38. Essex, J.; Jorgensen, W. L. An empirical boundary potential for water droplet simulations. J. Comput. Chem. 1995, 16 (8), 9510-972.
39. Press, W. H.; Flanney, B. P.; Teukolsky, S. A.; Vetterling, W. T. In Numerical Recipes. The Art of Scientific Computing; Cambridge University Press: CV Cambridge, 1986.
40. Hockney, R. W. The potential calculation and some applications. Methods Comput. Phys. 1970, 9, 136-211.
41. Woodcock, L. V. Isothermal molecular dynamics calculations for liquid salts. Chem. Phys. Lett. 1971, 10, 257-261.
42. Berendsen, H. C. J.; Postma, J. P. M.; van Gunsteren, W. F.; DiNola, A.; Haak, J. R. Molecular Dynamics with Coupling to an External Bath. J. Chem. Phys. 1984, 81, 3684-3690.
43. Auffinger, P.; Beveridge, D. L. A simple test for evaluating the truncation effects in simulations of systems involving charged groups. Chem. Phys. Lett. 1995, 234, 413-415.
44. Jorgensen, W. L.; Nguyen, T. B. Monte Carlo simulations of the hydration of substituted benzenes with opls potential functions. J. Comput. Chem. 1993, 14 (2), 195-205.
45. Goldblum, A. On the mechanism of proteinases. In Computational Approaches to Biochemical Reactivity; Náray-Szabó, G., Warshel, A., Eds.; Kluwer Academic Publishers: Dordrecht, 1997; pp 295-340.